From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.
Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback